InvestorsHub Logo
Followers 73
Posts 6212
Boards Moderated 0
Alias Born 05/01/2011

Re: None

Sunday, 12/02/2018 10:17:17 AM

Sunday, December 02, 2018 10:17:17 AM

Post# of 425847
I think AMRN is going to be cautious and deferential to the FDA, precisely as they have been ever since they won the 1st Amendment suit and then renegotiated the SPA.

And I think the FDA is going to reward this deference with a priority review, and a broad label expansion.

That's what I think.

“The trick is in what one emphasizes. We either make ourselves miserable, or we make ourselves happy. The amount of work is the same.” Carlos Castaneda

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News